Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Background CD47 is an innate immune checkpoint that binds signal regulatory protein alpha (SIRPα) and delivers a “do not eat” signal to suppress macrophage phagocytosis. Overexpression of CD47 can allow tumor cells to escape immune surveillance. TTI-621 (SIRPαFc) is a fusion protein consisting of th...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2020-11, Vol.136 (Supplement 1), p.41-43
Hauptverfasser:	Horwitz, Steven M., Foran, James M., Maris, Michael, Sawas, Ahmed, Okada, Craig, Feldman, Tatyana A., Minden, Mark D., Sokol, Lubomir, Mei, Matthew, Flinn, Ian W., Villa, Diego, Percival, Mary-Elizabeth M., Jagadeesh, Deepa, Savage, Kerry J., Akilov, Oleg E., Diefenbach, Catherine, Kim, Youn H., Lin, Gloria H.Y., Catalano, Tina, Petrova, Penka S., Uger, Bob, Molloy, Naomi, Large, Kathleen, Shou, Yaping, Ansell, Stephen M.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!